Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxychloroquine + temozolomide
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of hydroxychloroquine (HCQ) and temozolomide (TMZ). Temozolomide is an alkylating agent that causes DNA damage through methylation of adenine/guanine residues, while hydroxychloroquine functions as an autophagy inhibitor. The combination works by enhancing cell death in cancer cells, as blocking autophagy with hydroxychloroquine augments the cytotoxic effects of temozolomide. This approach has shown particular promise in treating advanced solid malignancies, especially metastatic melanoma and glioblastoma.
02
Targets
AGT (O6-methylguanine-DNA methyltransferase)NeuraminidaseDNA
Beyond the preview
Go deeper on hydroxychloroquine + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxychloroquine + temozolomide.